Work

Cabazitaxel for metastatic castration-resistant prostate cancer (mCRPC): Interim safety and quality-of-life (QOL) data from the U.K. early access program (NCT01254279).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.5_suppl.44

Authors: Amit Bahl, Susan Masson, Zafar Malik, Alison J Birtle, Santhanam Sundar, Robert J Jones, Nicholas David James, Malcolm David Mason, Satish Kumar, David Bottomley, Anna Lydon, Simon Chowdhury, James Wylie, Johann Sebastian De Bono

Institutions: Nottingham University Hospitals NHS Trust, Beatson West of Scotland Cancer Centre, St James's University Hospital, Velindre Cancer Centre, Royal Preston Hospital, University of Birmingham

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4250978370

Cites:

Cited by: 8

Related to: 10